Rheumatology Unit, Department of Medicine, University of Pisa, Italy.
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):948-958. Epub 2018 Dec 6.
Osteoporosis is a generalised bone disease characterised by decreased bone mass and deterioration of bone microarchitecture predisposing to fragility fractures. Bone fractures are a remarkable social and economic health problem, and several studies have been carried out in order to reduce their occurrence. Inhibiting bone resorption and increasing bone formation are the mainstay of treatment, anti-catabolic and anabolic, respectively. This review highlights the most recent advances in osteoporosis and reports the evidence of efficacy and safety of anabolic treatment of osteoporosis, as evaluated by randomised, controlled trials published during 2017. As the most common form of secondary osteoporosis, we will also discuss the 2017 state-of-the-art on pathogenesis and treatment of glucocorticoid-induced osteoporosis.
骨质疏松症是一种全身性骨骼疾病,其特征是骨量减少和骨微观结构恶化,易导致脆性骨折。骨折是一个显著的社会和经济健康问题,已经进行了多项研究以减少其发生。抑制骨吸收和增加骨形成分别是治疗的主要方法,分别为抗分解代谢和合成代谢。本综述重点介绍了骨质疏松症的最新进展,并报告了 2017 年发表的随机对照试验评估的骨质疏松症合成代谢治疗的疗效和安全性证据。作为最常见的继发性骨质疏松症,我们还将讨论 2017 年糖皮质激素诱导性骨质疏松症的发病机制和治疗的最新进展。